Evidence map›Paper›PMID 29616099›Full record

ArticleOncology letters2018

Analysis of H3K27me3 expression and DNA methylation at CCGG sites in smoking and non-smoking patients with non-small cell lung cancer and their clinical significance.

Kunshou Zhu, Yujie Deng, Guoxing Weng, Dan Hu, Cheng Huang, Keitaro Matsumoto, Takeshi Nagayasu, Takehiko Koji, Xiongwei Zheng, Wenhui Jiang and 4 more

Abstract read
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kunshou ZhuDepartment of Oncological Surgery, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian 350014, P.R. China.
Yujie DengDepartment of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, P.R. China.
Guoxing WengDepartment of Cardiac Surgery, Fujian Provincial Hospital, Fuzhou, Fujian 350001, P.R. China.
Dan HuDepartment of Pathology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital Fuzhou, Fuzhou, Fujian 350014, P.R. China.
Cheng HuangDepartment of Medical Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital Fuzhou, Fuzhou, Fujian 350014, P.R. China.
Keitaro MatsumotoDivision of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Nagasaki 852-8501, Japan.
Takeshi NagayasuDivision of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Nagasaki 852-8501, Japan.
Takehiko KojiDepartment of Histology and Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki 852-8523, Japan.
Xiongwei ZhengDepartment of Pathology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital Fuzhou, Fuzhou, Fujian 350014, P.R. China.
Wenhui JiangDepartment of Pathology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital Fuzhou, Fuzhou, Fujian 350014, P.R. China.
Gen LinDepartment of Medical Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital Fuzhou, Fuzhou, Fujian 350014, P.R. China.
Yibin CaiDepartment of Oncological Surgery, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian 350014, P.R. China.
Guibin WengDepartment of Oncological Surgery, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian 350014, P.R. China.
Xiaohui ChenDepartment of Oncological Surgery, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian 350014, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Smoking frequently leads to epigenetic alterations, including DNA methylation and histone modifications. The effect that smoking has on the DNA methylation levels at CCGG sites, the expression of trimethylation of histone H3 at lysine 27 (H3K27me3) and enhancer of zeste homolog 2 (EZH2), and their interactions in patients with non-small cell lung cancer (NSCLC) were analyzed. There were a total of 42 patients with NSCLC, 22 with adenocarcinomas and 20 with squamous cell carcinomas enrolled in the present study. Expression of H3K27me3, EZH2 and proliferating cellular nuclear antigen (PCNA) were immunohistochemically detected. DNA methylation at CCGG sites was evaluated via histoendonuclease-linked detection of DNA methylation sites. The apoptotic index of cancerous tissues obtained from patients of different smoking statuses was evaluated via the terminal deoxynucleotidyl-transferase-mediated dUTP-biotin nick end labeling method. The association with clinicopathological data was calculated relative to different smoking statuses. Compared with the non-smokers, smokers with NSCLC exhibited a significantly lower apoptotic index (P<0.05), and frequently had a lower level of DNA methylation at CCGG sites, lower H3K27me3 expression and a higher EZH2 expression (P<0.05). DNA methylation levels at CCGG sites were negatively correlated to the Brinkman index (P=0.017). Furthermore, there was a parallel association between the H3K27me3 and EZH2 expression levels in the majority of smokers, whereas in the majority of non-smokers, there was a diverging association (P=0.015). There was a diverging association between the PCNA and EZH2 expression levels in the majority of smokers; however, in the majority of non-smokers, there was a parallel association (P=0.048). In addition, the association between the CCGG methylation ratio and immunohistochemical expression of H3K27me3 was a parallel association in the majority of smokers, while in the majority of non-smokers there was a diverging association (P=0.049). Conclusively, patients with NSCLC and different smoking statuses exhibit different epigenetic characteristics. Additionally, DNA methylation levels at the CCGG sites may have the ability to determine associations between the expression levels of H3K27me3, EZH2 and PCNA.

Indexed as

DNA methylationEZH2non-small cell lung cancersmokingtrimethylation of histone H3 at lysine 27

Identifiers

PMID29616099
PMCPMC5876441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.